Karo Pharma (Cancer Project KB9520) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Karo Pharma (Cancer Project KB9520) General Information

Description

KB9520 estrogen receptor cancer drug developed for cancer treatment. The asset provides various type of cancer treatment.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Nybrokajen 7
  • Stockholm
  • Sweden
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Acquirer
Vertical(s)
Corporate Office
  • Nybrokajen 7
  • Stockholm
  • Sweden

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Karo Pharma (Cancer Project KB9520) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Karo Pharma (Cancer Project KB9520)‘s full profile, request access.

Request a free trial

Karo Pharma (Cancer Project KB9520) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Karo Pharma (Cancer Project KB9520)‘s full profile, request access.

Request a free trial

Karo Pharma (Cancer Project KB9520) FAQs

  • Where is Karo Pharma (Cancer Project KB9520) headquartered?

    Karo Pharma (Cancer Project KB9520) is headquartered in Stockholm, Sweden.

  • What industry is Karo Pharma (Cancer Project KB9520) in?

    Karo Pharma (Cancer Project KB9520)’s primary industry is Buildings and Property.

  • Is Karo Pharma (Cancer Project KB9520) a private or public company?

    Karo Pharma (Cancer Project KB9520) is a Private company.

  • What is Karo Pharma (Cancer Project KB9520)’s current revenue?

    The current revenue for Karo Pharma (Cancer Project KB9520) is .

  • Who are Karo Pharma (Cancer Project KB9520)’s investors?

    Karo Healthcare has invested in Karo Pharma (Cancer Project KB9520).

  • When was Karo Pharma (Cancer Project KB9520) acquired?

    Karo Pharma (Cancer Project KB9520) was acquired on 24-Oct-2016.

  • Who acquired Karo Pharma (Cancer Project KB9520)?

    Karo Pharma (Cancer Project KB9520) was acquired by Vivesto.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process